Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome which was approved by the U.S. Food and Drug Administration on March 26, 2025. Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. Soleno has established a comprehensive support program, Soleno ONE, to assist patients, caregivers and healthcare providers with access to VYKAT XR.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics put volume heavy and directionally bearish
- Positive Outlook for Soleno Therapeutics Following FDA Approval and Strong Financial Position
- Soleno Therapeutics price target raised to $100 from $70 at H.C. Wainwright
- Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
- Soleno Therapeutics price target raised to $108 from $74 at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue